Optimizing regional infusion treatment strategies for melanoma of the extremities

Expert Review of Anticancer Therapy

Volumn 9, Issue 11, 2009, Pages 1599-1609

  Coleman, Andrew ^b   Augustine, Christina K ^a   Beasley, Georgia ^a   Sanders, Gretchen ^a   Tyler, Douglas ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADH 1; Bevacizumab; Butathione sulfixime; Dasatinib; Hyperthermic isolated limb perfusion; IFN ; In transit melanoma; Isolated limb infusion; Melanoma; Melphalan; O6 benzylguanine; Regional chemotherapy; Satellitosis; Sorafenib; Temozolomide; TNF

Indexed keywords

ADH 1; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUTATHIONE SULFIXIME; CARBOPLATIN; CISPLATIN; DACARBAZINE; DACTINOMYCIN; ENZYME INHIBITOR; EXHERIN; FOTEMUSTINE; GLUTAMATE CYSTEINE LIGASE INHIBITOR; MELPHALAN; PENTAPEPTIDE; SORAFENIB; TEMOZOLOMIDE; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER TISSUE; CLINICAL TRIAL; DRUG INFUSION; DRUG RESPONSE; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; ISOLATED LIMB INFUSION; LIMB DISEASE; LIMB PERFUSION; MELANOMA; NONHUMAN; PREDICTION; REGIONAL PERFUSION; REVIEW; STANDARDIZATION; SYSTEMIC DISEASE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; SKIN NEOPLASMS;

EID: 71949107008     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.126     Document Type: Review

References (66)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 146 (Suppl. 61), 1-6 (2002).
2. American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society, GA, USA (2008).
3. Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med. 355(1), 51-65 (2006).
4. Balch CM, Houghton AN, Soper AJ, Soong S, Thompson JF. Isolated Limb Infusion. Quality Medical Publishing, MO, USA (2008).
5. Koops HS, Vaglini M, Suciu S et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized Phase III trial: European Organization for Research and Treatment of Cancer Malignant Melanoma cooperative group protocol 18832, the World Health Organization Melanoma Program trial 15, and the North American Perfusion Group Southwest Oncology group-8593. J. Clin. Oncol. 16(9), 2906-2912 (1998).
6. Pawlik TM, Ross MI, Johnson MM et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann. Surg. Oncol. 12(8), 587-596 (2005).
7. Kretschmer L, Beckmann I, Thoms KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann. Surg. Oncol. 13(8), 1105-1112 (2006). (Pubitemid 44337970)
8. Balch CM, Houghton AN, Sober A, Soong S. Recurrent Regional Metastases and Their Management. Quality Medical Publishing, MO, USA (1998).
9. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 148(4), 616-632 (1958).
10. Ariyan CE, Brady MS. History of regional chemotherapy for cancer of the extremities. Int. J. Hyperthermia 24(3), 185-192 (2008).
11. Creech O Jr, Krementz ET, Ryan RF, Reemtsma K, Winblad JN. Experiences with isolation-perfusion technics in the treatment of cancer. Ann. Surg. 149(5), 627-640 (1959).
12. Cavaliere R, Ciocatto EC, Giovanella BC et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20(9), 1351-1381 (1967).
13. Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg. Gynecol. Obstet. 129(2), 305-308 (1969).
14. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann. Surg. 245(4), 591-596 (2007). (Pubitemid 46555663)
15. Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55(11), 2638-2644 (1985). (Pubitemid 15092151)
16. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am. J. Surg. 150(1), 32-35 (1985).
17. Kroon BB, Van Geel AN, Benckhuijsen C, Wieberdink J. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res. 7(3 Pt B), 441-442 (1987). (Pubitemid 17151928)
18. Di Filippo F, Calabro A, Giannarelli D et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63(12), 2551-2561 (1989). (Pubitemid 19152772)
19. Kroon BB, Klaase JM, van Geel BN, Eggermont AM, Franklin HR, van Dongen JA. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur. J. Cancer 29A(3), 325-328 (1993).
20. Klaase JM, Kroon BB, van Geel AN et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J. Am. Coll. Surg. 178(6), 564-572 (1994).
21. Aloia TA, Grubbs E, Onaitis M et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch. Surg. 140(11), 1115-1120 (2005). (Pubitemid 41668683)
22. Cornett WR, McCall LM, Petersen RP et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J. Clin. Oncol. 24(25), 4196-4201 (2006). • Multicenter randomized, controlled trial elucidating the efficacy and safety of hyperthermic isolated limb perfusion with melphalan with or without the addition of TNF-a.
23. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch. Surg. 139(11), 1237-1242 (2004).
24. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J. Surg. 19(3), 363-368 (1995).
25. Beasley GM, Caudle A, Petersen RP et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J. Am. Coll. Surg. 208(5), 706-715 (2009).
26. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin. Surg. Oncol. 14(3), 238-247 (1998).
27. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor a in combination with interferon g and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10(1), 52-60 (1992).
28. Kroon HM, Lin DY, Kam PC, Thompson JF. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann. Surg. Oncol. 16(5), 1193-1201 (2009).
29. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 20(2), 287-289 (1991).
30. van de Merwe SA, van den Berg AP, Kroon BB, van den Berge AW, Klaase JM, van der Zee J. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int. J. Hyperthermia 9(2), 205-217 (1993).
31. Thompson JF, Morton DL, Kroon BB. Isolated Limb Perfusion for Melanoma: Technical Aspects. Martin Dunitz, London, UK (2004).
32. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann. Surg. Oncol. 9(2), 127-136 (2002). (Pubitemid 34259697)
33. Parsons PG, Carter FB, Morrison L, Regius MS. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 41(4), 1525-1534 (1981). (Pubitemid 11146791)
34. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann. Surg. Oncol. 15(11), 3003-3013 (2008). • Outlines the 14-year experience of isolated limb infusion outcomes at the Sydney Melanoma Unit (Australia).
35. Beasley GM, Petersen RP, Yoo J et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann. Surg. Oncol. 15(8), 2195-2205 (2008). • Comparison of response and toxicity outcomes from isolated limb infusion and hyperthermic isolated limb perfusion from the Duke University Medical Center (NC, USA).
36. Brady MS, Brown K, Patel A, Fisher C, Marx W. A Phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann. Surg. Oncol. 13(8), 1123-1129 (2006). (Pubitemid 44337972)
37. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can. J. Surg. 44(3), 189-192 (2001). (Pubitemid 32538770)
38. Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur. J. Surg. Oncol. 30(10), 1107-1112 (2004). (Pubitemid 40267817)
39. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 115(9), 1932-1940 (2009).
40. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch. Surg. 132(8), 903-907 (1997).
41. Cheng TY, Grubbs E, Abdul-Wahab O et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am. J. Surg. 186(5), 460-467 (2003). (Pubitemid 37352828)
42. Vrouenraets BC, Hart GA, Eggermont AM et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J. Am. Coll. Surg. 188(5), 522-530 (1999).
43. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin. Surg. Oncol. 14(3), 224-231 (1998).
44. McMahon N, Cheng TY, Beasley GM et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann. Surg. Oncol. 16(4), 953-961 (2009).
45. Ko SH, Ueno T, Yoshimoto Y et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin. Cancer Res. 12(1), 289-297 (2006). (Pubitemid 43166206)
46. Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am. J. Surg. 188(5), 532-537 (2004). (Pubitemid 39491100)
47. Grubbs EG, Abdel-Wahab O, Cheng TY et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J. Am. Coll. Surg. 199(3), 419-427 (2004). (Pubitemid 39120057)
48. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30(6), 445-600 (1995).
49. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44(11), 5427-5431 (1984).
50. Suzukake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol. 31(1), 121-124 (1982). (Pubitemid 12198275)
51. Robson CN, Lewis AD, Wolf CR et al. Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res. 47(22), 6022-6027 (1987).
52. Suzukake K, Vistica BP, Vistica DT. Dechlorination of l-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32(1), 165-167 (1983). (Pubitemid 13168356)
53. Grubbs EG, Ueno T, Abdel-Wahab O et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 136(2), 210-218 (2004). (Pubitemid 39037656)
54. Ueno T, Ko SH, Grubbs E et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol. Cancer Ther. 5(3), 732-738 (2006).
55. Yoshimoto Y, Augustine CK, Yoo JS et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol. Cancer Ther. 6(5), 1492-1500 (2007). (Pubitemid 46954016)
56. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993). (Pubitemid 23132159)
57. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997). (Pubitemid 27441066)
58. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
59. Dickson PV, Hamner JB, Sims TL et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13(13), 3942-3950 (2007).
60. Augustine CK, Yoshimoto Y, Gupta M et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 68(10), 3777-3784 (2008).
61. Beasley GM, McMahon N, Sanders G et al. A Phase I study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115(20), 4766-4774 (2009).
62. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002). (Pubitemid 34716871)
63. Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21(46), 7001-7010 (2002). (Pubitemid 35252974)
64. Niu G, Wright KL, Huang M et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13), 2000-2008 (2002).
65. Augustine CK, Yoo JS, Potti A et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin. Cancer Res. 15(2), 502-510 (2009).
66. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 http://ctep.cancer.gov